In addition, as several specific inhibitors of MIF are being advanced from the preclinical setting to human patients our data may suggest the possibility that some of the analytes presently evaluated may represent suitable biomarkers predictive for a therapeutic response to MIF inhibitors in patients with RA and possibly other immunoinflammatory and autoimmune diseases [9]. The gene discussed is MIF; the disease is autoimmune disease.